Genexine Statistics

Total Valuation

Genexine has a market cap or net worth of KRW 231.04 billion. The enterprise value is 247.20 billion.

Market Cap	231.04B
Enterprise Value	247.20B

Important Dates

The next estimated earnings date is Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Genexine has 45.48 million shares outstanding. The number of shares has increased by 21.23% in one year.

Current Share Class	n/a
Shares Outstanding	45.48M
Shares Change (YoY)	+21.23%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	4.98%
Owned by Institutions (%)	5.25%
Float	37.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	36.11
PB Ratio	0.73
P/TBV Ratio	0.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.53
EV / Sales	42.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.84

Financial Position

The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.24.

Current Ratio	1.29
Quick Ratio	1.05
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-1.62
Interest Coverage	-11.39

Financial Efficiency

Return on equity (ROE) is -17.31% and return on invested capital (ROIC) is -6.98%.

Return on Equity (ROE)	-17.31%
Return on Assets (ROA)	-6.70%
Return on Capital (ROIC)	-6.98%
Revenue Per Employee	67.53M
Profits Per Employee	-634.02M
Employee Count	86
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.16% in the last 52 weeks. The beta is 0.76, so Genexine's price volatility has been lower than the market average.

Beta (5Y)	0.76
52-Week Price Change	-42.16%
50-Day Moving Average	5,667.10
200-Day Moving Average	6,752.03
Relative Strength Index (RSI)	36.21
Average Volume (20 Days)	120,398

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genexine had revenue of KRW 5.81 billion and -54.53 billion in losses. Loss per share was -1,320.62.

Revenue	5.81B
Gross Profit	-196.75M
Operating Income	-43.18B
Pretax Income	-54.51B
Net Income	-54.53B
EBITDA	-38.14B
EBIT	-43.18B
Loss Per Share	-1,320.62

Full Income Statement

Balance Sheet

The company has 52.50 billion in cash and 68.67 billion in debt, giving a net cash position of -16.16 billion or -355.42 per share.

Cash & Cash Equivalents	52.50B
Total Debt	68.67B
Net Cash	-16.16B
Net Cash Per Share	-355.42
Equity (Book Value)	288.07B
Book Value Per Share	6,949.76
Working Capital	14.87B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -34.02 billion and capital expenditures -8.28 billion, giving a free cash flow of -42.30 billion.

Operating Cash Flow	-34.02B
Capital Expenditures	-8.28B
Free Cash Flow	-42.30B
FCF Per Share	-930.15

Full Cash Flow Statement

Margins

Gross Margin	-3.39%
Operating Margin	-743.54%
Pretax Margin	-938.51%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Genexine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.23%
Shareholder Yield	-21.23%
Earnings Yield	-26.00%
FCF Yield	-18.31%

Stock Splits

The last stock split was on January 11, 2023. It was a forward split with a ratio of 1.3.

Last Split Date	Jan 11, 2023
Split Type	Forward
Split Ratio	1.3

Scores

Genexine has an Altman Z-Score of 2.63. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.63
Piotroski F-Score	n/a